tbuckley/cabot-search huggingface dataset:
Abstract 3465: shRNA against uPA and uPAR enhances secretion of sVEGFr1 in tumor endothelial and glioblastoma cells independent of GMCSF
Authors: Hari Raghu, Christopher S. Gondi, Arun Kumar Nalla, Jasti S. Rao
Journal: Cancer Research (2011)

Abstract The uPA/uPAR system is known to play a critical role in angiogenesis of glioblastomas. Previously, using protein array antibody analysis, we demonstrated that shRNA against uPA and uPAR (pU2) inhibits angiogenesis in vitro and in vivo by regulating a number of pro-angiogenic, angiostatic and anti-angiogenic molecules. GMCSF, a pleiotropic cytokine that stimulates proliferation, differentiation, and survival of various hematopoietic cells, was significantly inhibited in U87MG and 4910 cells co-cultured with endothelial cells and transfected with pU2. In this study, we evaluated the effect of shRNA against uPA and uPAR on GMCSF, sVEGFr1, GMCSF receptors and GMCSF-induced signaling and its significance on angiogenesis in glioblastoma and endothelial cells. ELISA revealed that simultaneous knockdown of uPA and uPAR in U87MG, 4910 and HMEC cells decreased secretion of GMCSF but enhanced the secretion of sVEGFr1, a known scavenger of VEGF-A. The results of the western blot analysis were consistent with our ELISA results. In endothelial cells treated with shRNA against GMCSF, recombinant uPA (ruPA) resulted in activation of GMCSFR-α and GMCSFR-β at very early time points. Moreover, endothelial tube formation was inhibited with the addition of rsVEGFr1, and antibody to rsVEGFr1 blocked GMCSF-induced tube formation in endothelial cells. The addition of ruPA to endothelial and glioblastoma cells activated phosphorylation of JAK2 and STAT3. p27, an effector of the GMCSF signaling pathway, was downregulated in puPA-, puPAR- and pU2-transfected U87MG and 4910 cells. To determine the significance of these events in vivo, nude mice were checked for levels of GMCSF and sVEGFr1 before and after tumor formation and also after treatment with puPA, puPAR and pU2. Results showed increased levels of sVEGFr1 but decreased levels of GMCSF in shRNA treated mice in comparison to controls. Taken together, these results suggest that knockdown of uPA/uPAR in tandem induces sVEGFr1, which plays a vital role in inhibition of angiogenesis, and its secretion is independent of GMCSF in endothelial cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3465. doi:10.1158/1538-7445.AM2011-3465
Appetite effect of dronabinol.
Authors: J A Beal
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.7.1524 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8021744 Appetite effect of dronabinol. J A BealxJ A BealSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.7.1524 PDF "Appetite effect of dronabinol.." Journal of Clinical Oncology, 12(7), pp. 1524–1525© 1994 by American Society of Clinical Oncology
Celecoxib in Patients with Asthma and Aspirin Intolerance
Authors: Barbro Dahlén, Andrew Szczeklik, John J. Murray
Journal: New England Journal of Medicine (2001)

To the Editor: In some patients with asthma, the administration of aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) leads to bronchospasm.1 The reaction is related to inhibition of the cyclooxygenase (COX) enzyme that catalyzes prostaglandin production. Two isoforms of the enzyme (COX-1 and COX-2) have been identified, but it is not known which isoform is involved in the intolerance of NSAIDs. We examined 27 patients for bronchospasm after the administration of celecoxib,2 a selective COX-2 inhibitor recently introduced as an antiinflammatory treatment for arthritis in patients with asthma and aspirin intolerance. The patients (17 women and 10 men with a . . .
Vitamin D Intoxication Associated with an Over-the-Counter Supplement
Authors: Polyxeni Koutkia, Tai C. Chen, Michael F. Holick
Journal: New England Journal of Medicine (2001)

To the Editor: As a group, fat-soluble vitamins are lifesaving at physiologic levels and dangerous at megavitamin levels.1 For many people the word “vitamin” implies something that is beneficial and essential, not potentially poisonous.2 More than one third of people in the United States regularly use dietary supplements.3 We describe a patient with hypercalcemia associated with the ingestion of an over-the-counter vitamin D supplement. A 42-year-old man was hospitalized with symptoms of hypercalcemia of a few weeks' duration. For the past two years, he had been taking a supplement that contained vitamin D3. On admission his serum levels . . .
Human immunodeficiency virus (HIV)-associated duodenal lymphoma
Authors: S. Nakazuru, T. Yoshio, Y. Ogawa, K. Yuguchi, H. Hasegawa, Y. Sakakibara, Y. Kodama, T. Uehira, E. Mita
Journal: Endoscopy (2011)

A 68-year-old man was referred to our hospital for HIV treatment. He noticed melena on admission. Laboratory data showed anemia, with a hemoglobin level of 8.2 g/dL. The CD4 lymphocyte count was 101 cells/µL.
THU0166 Associations of Formal Education Level with Rheumatoid Arthritis (RA) Core Data Set Variables and Indices in Korean Patients
Authors: S.-H. Park, I. Castrejón, J.-Y. Choe, S.-K. Kim, H.-J. Lee, T. Pincus
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Poor health is associated with low socioeconomic status (SES), with higher prevalence, greater severity and earlier mortality of many diseases, including rheumatoid arthritis (RA). However, a variable describing SES is not included in many clinical research reports, in contrast to age and gender, which are almost always included as demographic potential confounders of differences in patient status and treatment responses. The most easily measured SES variable is formal education level (EDUC), which has been interpreted as an available surrogate for patient actions and attitudes that may affect health. <h3>Objectives</h3> To analyze RA core data set variables, as well as rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), and 4 RA indices for possible associations with EDUC in a cohort of Korean RA patients seen in usual care. <h3>Methods</h3> All 7 RA core data set measures are collected in consecutive patients with RA seen in a Korean setting by 4 rheumatologists. Patients were classified in 3 EDUC categories: &lt;7 years (n=77; mean age 62.6 years), 7-9 years (n=102; mean age 58.6), and &gt;9 years (n=220; mean age 52.9). Possible associations with EDUC were analyzed for each of the 7 RA core data set measures, RF, ACPA, and 4 RA indices: DAS28, SDAI, CDAI and RAPID3 [an index of only the 3 patient self-report core data set measures found on an MDHAQ: physical function, pain and patient global estimate of status (PATGL)]. The data were analyzed by analysis of variance (ANOVA) adjusted for age, gender and disease duration, and by regressions for each variable, with EDUC, age, gender and disease duration as independent variables. <h3>Results</h3> Patients with lower EDUC had higher scores, indicating more severe disease activity, for all core data set measures, statistically significant for tender joint count (TJC28), physical function, pain, PATGL and ESR, but not for swollen joint count (SJC28), physician global estimate (DOCGL) and CRP. RF and ACPA did not show this trend. All 4 indices – DAS28, SDAI, CDAI and RAPID3 – differed significantly according to EDUC, adjusted for age, gender and disease duration (p&lt;0.001). <h3>Conclusions</h3> Significant associations of low EDUC with greater disease severity according to most RA core data set measures and 4 indices were seen in 399 Korean RA patients. <h3>Disclosure of Interest</h3> None Declared
PWE-181 Pancreatic exocrine function after major upper gastrointestinal surgery measured with a carbon 13 mixed triglyceride breath test
Authors: S Ward, R Cade, S Mackay, S Hassen, S Banting, P Gibson
Journal: Gut (2012)

<h3>Introduction</h3> Major upper gastrointestinal resectional surgery, including oesophagectomy, gastrectomy and pancreatico-duodenectomy, can result in post-operative nutritional difficulties, which may in part be associated with reduced pancreatic exocrine function, but there is debate in the literature about the actual proportion of these patients that have pancreatic exocrine insufficiency which may then benefit from oral supplementation. The Carbon 13 labelled mixed triglyceride breath test (C13-MTG-BT) was used to indirectly measure pancreatic exocrine function in post-operative patients and these results were compared to the test performed in control subjects. <h3>Methods</h3> 30 normal subjects, 15 post-oesophagectomy patients, 15 post-gastrectomy patients and 10 post-pancreatico-duodenectomy patients were recruited to undertake the C13-MTG-BT at Box Hill Hospital, Melbourne, Australia, between August 2009 and January 2011. The C13-MTG-BT was performed using 200 mg of C13-MTG substrate and measured using an infra-red isotope spectrometer. The cumulative percentage of ingested C13 exhaled after 6 h and the time at peak rate of C13 excretion were measured in all subjects and compared between groups, with statistical significance calculated using the Student t test. <h3>Results</h3> The mean cumulative percentage of ingested C13 exhaled after 6 h in the control group was 28.6% with a SD of 8.8%. The cumulative percentage exhaled after 6 h in each post-operative group compared with the control group was not significantly different. The time of peak rate of C13 excretion was earlier in the post-operative groups compared with the control group. <h3>Conclusion</h3> This study has not found a large percentage of patients post major upper gastrointestinal resections with measurable reduction in pancreatic exocrine function using the C13-MTG-BT, which is in contrast to the literature. The finding of earlier times of peak rate of excretion imply the post-operative patients tend to have more rapid gut transit. Larger and prospective studies using this test or another pancreatic function test may be useful to detect the proportion of post-operative patients with pancreatic exocrine insufficiency that may then benefit from pancreatic exocrine supplementation. <h3>Competing interests</h3> None declared.
Abstract 4069: The p47 Phox mediated redox-signal promotes myogenesis via p38 MAPK regulated microRNA-206
Authors: Junkyu Song, Young Eun Choi, Hye Ok Kim, Chang Hoon Cho, Kyung-Sik Yoon
Journal: Cancer Research (2010)

Abstract miR-206 is reported that one of the skeletal muscle specific myogenic factors which are halt the cell cycle via inhibition of DNA polymerase-alpha. So far, MyoD and AP1 are as well as known for miR-206 transcription factors. In this study, we take the evidence of another transcription factor MEF-2 which have a capacity for miR-206 expression in myogenesis. In addition, a novel miR-206 transcription factor is belonging to p38 MAPK activities that can be regulated by p47 Phox mediated redox-signal. It is hypothesis for a novel role of myogenic miR-206 regulation that p47 Phox generated redox-signal contributes to skeletal muscle differentiation via p38 MAPK activated miR-206. Followed the hypothesis, we were analysis the miR-206 promoter region (&amp;gt;-2k) by MatInspector (Promotor analysis tool, www.genomatix.de) for found out another plausible transcription factors and compare the miR-206 expression levels in SB203580 (p38 MAPK inhibitor), DPI (p47 Phox inhibitor) treated and differentiation condition by real-time PCR. Then, measuring the differentiation induced ROS during myogenesis by FACS. Moreover, we analyzed the expressions of myogenic factors and cell cycle involved molecules, including DNA polymerase-alpha, with immunoblotting. As a result, we hunt out a specious myogenic transcription factor MEF-2 that was not reported as a miR-206 expression factor. Both MEF-2 upstream activator p38 MAPK and p38 MAPK stimulating redox generator p47 Phox inhibition were accompanied with miR-206 down regulation. Besides, hindering of p38 MAPK and p47 Phox observed restoration of DNA polymerase-alpha transcription/translation levels in myogenic condition. Accordingly, we suggest that ROS activated p38 MAPK down-stream transcription factor MEF-2 may showed to a novel regulation factor of miR-206 in mouse skeletal muscle myogenesis. Key words: microRNA-206(miR-206), p47 Phox, p38 MAPK, MEF-2 Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4069.
A Simple Cervicomediastinal Exploration for Tissue Diagnosis of Intrathoracic Disease
Authors: Dwight E. Harken, Harrison Black, Roy Clauss, Robert E. Farrand
Journal: New England Journal of Medicine (1954)

SINCE Daniels's1 report (1949) on biopsy of scalene lymph nodes for the diagnosis of intrathoracic diseases, considerable interest has been manifested in the application of this technic. Others2 , 3 have substantiated its usefulness. For the past three years we have employed a procedure that supplements the advantages of scalene-node biopsy by the addition of an exploration of the superior mediastinum. This procedure has been performed in cases of pulmonary disease presenting diagnostic problems. It is also used in patients having suspected or proved carcinoma of the lung to determine operability. It is emphasized that, in none of the patients described here . . .
FRI0426 Distribution of short and long-term sick leave in musculoskeletal disorders
Authors: J. Hubertsson, M. Englund, I.F. Petersson
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Musculoskeletal diseases are major causes of sick leave. The patterns of short and long term sick leave in the different disease groups are not well studied. <h3>Objectives</h3> To examine variations in the length of sick leave between groups of major musculoskeletal disorders (MSDs). <h3>Methods</h3> We collected information on all sick leave certificates issued in 22 public primary health care units and the 2 hospitals of the North West region of the Skåne County in Sweden (population 250 000) 2009-2010. We then calculated length of periods of sick leave and proportion of short (&lt;15 days), medium (15-90 days) and long (&gt;90 days) sick leaves for different disorders using the three character level diagnostic codes of the musculoskeletal disease (M) chapter for the ICD-10 coding system. Correlation with age was tested by Pearson correlation. <h3>Results</h3> We found 3563 (51% for women) sick leave periods issued caused by MSDs (ICD-10 M00-M99), 17% (613) &lt;15 days, 63% (2234) 15-90 days and 20% (716) &gt;90 days. Length of periods was increasing with higher age (Pearson correlation, r=0.102, p&lt;0.001). The 5 MSDs with most sick leave episodes were back pain (M54), myalgia (M79), disc disorders (M51), knee osteoarthritis (M17) and knee injuries (M23). The proportion of short and long sick leave periods differed significantly between the groups (p&lt;0.001) (Figure 1). <h3>Conclusions</h3> Distribution of short and long-term sick leave differs between the most common MSDs. Patients with back pain or myalgia had more short-term sick leave while knee osteoarthritis and disc disorders had a greater proportion of long-term sick leave. <h3>Disclosure of Interest</h3> None Declared
EFFICACY AND SAFETY OF PHARMACO-INVASIVE REPERFUSION STRATEGY VERSUS PRIMARY ANGIOPLASTY IN ST-ELEVATION MYOCARDIAL INFARCTION: SYSTEMATIC REVIEW WITH META-ANALYSIS OF 4220 PATIENTS ENROLLED IN RANDOMIZED CONTROLLED TRIALS AND COHORT STUDIES
Authors: Jun Pu, Ting Lv, Hang Zhao, Antonio C. Carvalho, Ben He
Journal: Journal of the American College of Cardiology (2015)
AB0481 Clinical features of tunisian patients with behçet's disease: a retrospective monocentric study
Authors: S. Bellakhal, F. Ajili, N. Boussetta, L. Metoui, S. Sayhi, J. Laabidi, B. Louzir, N. Ben Abdelhafidh, S. Othmani
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Behcet's disease is a multisystemic inflammatory disease characterized by recurrent oral and genital ulcers, skin lesions and uveitis. The diagnosis of Behcet's disease is based on clinical criteria. The etiology of the disease is unknown but the wide variations of ethnic prevalence and of the prevalence in the same ethnic group in different geographic areas indicates environmental triggering of a genetically determined disorder. <h3>Objectives</h3> We aimed to describe the demographic and clinical features of Behcet's in a Tunisian military population. <h3>Methods</h3> A retrospective analysis of the medical charts of 150 Behcet's disease patients seen in our internal medicine department between 1995 and 2010 was undertaken. Among them 85 patients fulfilled the International Study Group for Behcet's disease criteria and were included in the study. <h3>Results</h3> All patients were Tunisian originated from all the parts of Tunisia. They were 67 men and 18 women with a male to female ratio of 3.7. The mean age at the Behcet's disease diagnosis was 32 years (range, 15-65 years). Oral ulcers were seen in all patients and were the first feature of Behçet's disease in 31 patients (36.9%). Genital ulcers occurred in 70 (82.4%) patients, 65 patients (76.5%) had pseudofolliculitis and 48 (56.5%) had skeletal manifestations. Ocular involvement was observed in 33 (38.8%) patients, vascular lesions were seen in 28 (32.9%) patients and gastrointestinal lesions were the less frequent clinical feature seen in only 3 (3.5 %) patients. Patients have been followed up for a median of 70 months (range 1-276 months). Ten patients were lost sight and one patient died from massive pulmonary embolism. <h3>Conclusions</h3> The fact that there are ethnic and regional differences in Behçet's disease presentation is well known. Not only the frequency but also the type of organ lesions seems to differ between regions. These differences could be related to genetic and environmental influences. Perhaps this is why some prefer to see in BD a syndrome rather than a disease. Ocular manifestations were relatively common in our study and gastrointestinal lesions were square which is different from others populations. <h3>Disclosure of Interest</h3> None Declared
Abstract 3701: Phase II study of BIBF1120 in recurrent glioblastoma multiforme
Authors: Ulrik Lassen, Morten Mau-Soerensen, Aida Muhic, Eva Ehrnrooth, Hans S. Poulsen
Journal: Cancer Research (2012)

Abstract Background: BIBF 1120, a potent, orally available triple angiokinase inhibitor targeting VEGFR 1-3, PDGFR- α/-α, and FGFR 1-3, has shown promising clinical activity with a good safety profile in patients with advanced non-small cell lung cancer or ovarian cancer. The specific and simultaneous abrogation of these three pathways results in effective growth inhibition of both endothelial and perivascular cells. This may be more effective than inhibition of endothelial cell growth via the VEGF pathway alone. In addition, signalling via FGF-receptors has been identified as a possible escape mechanism for tumour angiogenesis when the VEGF pathway is disrupted. Recurrent glioblastomas (GBM) have an extremely poor prognosis and consequently new and innovative therapies are still needed. Accordingly, the purpose of this study was to assess the efficacy and safety of BIBF 1120 in two parallel groups of patients with recurrent GBM after radiotherapy and temozolomide (STD) or the same regimen and subsequent bevacizumab based therapy (BEV). Methods: Patients were included in one of two parallel groups depending of prior exposure to bevacizumab (STD or BEV). Inclusion critieria included recurrent GBM, PS 0-1, normal organ function, available archival tissue blocks, and measurable disease according to RANO guidelines. A total of 32 patients were to be enrolled in each group in a two-stage design including a stopping rule if less than 4/16 patient responded. BIBF-1120 was administered orally 200 mg bid, with weekly plasma sampling for the first 4 weeks and MRI assessement every 8 weeks. Primary endpoint was objective response rate. Secondary endpoints were safety, PFS and plasma and tissue biomarkers. Results: The study was prematurely stopped for after inclusion of 13 patients in the STD arm and 12 patients in the BEV arm. No objective responses were seen in either arm. One patient in the BEV arm has had stable disease for 8 months while the remainder of the patients in both arms progressed within the first 4 cycles. BIBF-1120 was very well tolerated with no observed grade III or IV adverse events. Most frequent adverse events were grade I-II hypertension, diarrhoea and fatigue, with a frequency of &amp;lt; 10%. Conclusion: BIBF-1120 was well tolerated, but did not show anti-tumor activity in recurrent GBM at the dose of 200 mg bid in this patient population. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3701. doi:1538-7445.AM2012-3701